Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma
China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...
CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...
Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving market approval from the...
Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...
Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...
Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...
Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation
The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...
Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...
Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization
China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...
Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...
Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...